Mersana Therapeutics, Inc. financial data

Symbol
MRSN on Nasdaq
Industry
Pharmaceutical Preparations
Location
840 Memorial Drive, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 365 % +7.48%
Debt-to-equity 383 % +78.2%
Return On Equity -261 % -16.4%
Return On Assets -54 % +24.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 122 M shares +6.97%
Common Stock, Shares, Outstanding 122 M shares +12.2%
Entity Public Float 364 M USD -9.79%
Common Stock, Value, Issued 12 K USD +9.09%
Weighted Average Number of Shares Outstanding, Basic 121 M shares +12.9%
Weighted Average Number of Shares Outstanding, Diluted 121 M shares +12.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 38.3 M USD +18.4%
Research and Development Expense 120 M USD -35.3%
General and Administrative Expense 52.8 M USD -15.6%
Nonoperating Income (Expense) 8.06 M USD +324%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -135 M USD +36.7%
Earnings Per Share, Basic -1.12 USD/shares +46.9%
Earnings Per Share, Diluted -1.12 USD/shares +46.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 75.2 M USD -38.8%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 188 M USD -33.5%
Property, Plant and Equipment, Net 3.83 M USD -3.86%
Operating Lease, Right-of-Use Asset 6.95 M USD -29.1%
Other Assets, Noncurrent 478 K USD -18.7%
Assets 198 M USD -33%
Accounts Payable, Current 3.09 M USD -83%
Employee-related Liabilities, Current 5.4 M USD +13.5%
Accrued Liabilities, Current 15.9 M USD -51.3%
Contract with Customer, Liability, Current 25.6 M USD -11%
Liabilities, Current 53.4 M USD -36%
Contract with Customer, Liability, Noncurrent 92 M USD -20.4%
Operating Lease, Liability, Noncurrent 4.22 M USD -45.7%
Other Liabilities, Noncurrent 638 K USD +356%
Liabilities 170 M USD -26.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -90 K USD -850%
Retained Earnings (Accumulated Deficit) -846 M USD -19%
Stockholders' Equity Attributable to Parent 28 M USD -56.5%
Liabilities and Equity 198 M USD -33%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32.7 M USD -12.6%
Net Cash Provided by (Used in) Financing Activities 5.83 M USD -73%
Net Cash Provided by (Used in) Investing Activities -72.5 M USD -5297%
Common Stock, Shares Authorized 350 M shares
Common Stock, Shares, Issued 122 M shares +12.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -99.4 M USD -1540%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 75.7 M USD -38.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 871 K USD +10.1%
Deferred Tax Assets, Valuation Allowance 239 M USD +25.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 242 M USD +24.9%
Operating Lease, Liability 8.4 M USD -26.1%
Depreciation 1.5 M USD +66.7%
Payments to Acquire Property, Plant, and Equipment 132 K USD -85.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -135 M USD +36.7%
Lessee, Operating Lease, Liability, to be Paid 9.47 M USD -29.8%
Operating Lease, Liability, Current 3.55 M USD +22.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.19 M USD +0.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.98 M USD +3.06%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.07 M USD -49.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.31 M USD -68.7%
Deferred Tax Assets, Operating Loss Carryforwards 127 M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.31 M USD -68.4%
Operating Lease, Payments 4.03 M USD +4.24%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 423 K USD +32.6%
Deferred Tax Assets, Net of Valuation Allowance 2.08 M USD -27%
Share-based Payment Arrangement, Expense 19.4 M USD -13.6%
Interest Expense 4.09 M USD +14.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%